Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing date is June 3, 2025, covering a share purchase executed on June 2, 2025. The transaction was conducted through Citigroup Global Markets Limited as part of GSK's existing share buyback programme, established via a non-discretionary agreement on February 24, 2025.
Key Financial Metrics and Transaction Details
The filing details a specific block of share repurchases rather than full financial statements. Key metrics for the June 2, 2025 transaction include:
- Shares Purchased: 564,381 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,506.50 GBp; highest price paid was 1,527.00 GBp.
- Volume-Weighted Average Price (VWAP): 1,518.04 GBp.
- Trading Venue: All purchases occurred on the London Stock Exchange (XLON).
- Treasury Share Holdings: Following this purchase, GSK holds 217,716,459 ordinary shares in treasury.
- Shares in Issue: 4,097,550,815 ordinary shares (excluding treasury shares).
- Treasury Voting Rights: Treasury shares represent 5.31% of total voting rights.
Material Changes and Programme Progress
Since the inception of the current buyback agreement on February 24, 2025, GSK has purchased an aggregate of 48,646,156 ordinary shares. The June 2 transaction represents a continuation of this programme. The filing does not provide comparative financial data (revenue, profit, cash flow) for the period, as it is a disclosure of a specific capital transaction.
Guidance, Outlook, and Risks
The filing contains a standard cautionary statement regarding forward-looking statements. GSK notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Investors are directed to the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2024 and the Q1 Results for 2025 for a detailed discussion of these risks. No new guidance or management commentary regarding operational outlook is provided in this specific filing.
Investor Verification Checklist
- Verify the total number of treasury shares held (217,716,459) against the company's latest capital structure disclosures.
- Confirm the remaining capacity under the buyback programme announced on February 24, 2025, given the cumulative purchase of 48,646,156 shares.
- Review the "Risk Factors" in the 2024 Form 20-F and Q1 2025 results for context on the company's broader financial health, as this filing does not contain operational metrics.
- Check the percentage of voting rights held in treasury (5.31%) to assess potential impacts on shareholder voting dynamics.